Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Roberto Machado Noa/LightRocket via Getty Images

The pharmaceutical industry is livid about a surprise change to Medicare drug policy that was slipped into the Senate budget deal. The bill would close the Medicare Part D "donut hole" in 2019, a year earlier than previously scheduled, and force drug companies to shoulder most of the cost.

Between the lines: Drug companies weren't the only ones taken by surprise. Many lawmakers didn't know this was coming, either. Yet as far as prescription drug policies go, this one is comparatively innocuous for the industry.

How it works: Medicare's donut hole puts seniors and disabled people on the hook for a large chunk of their prescription costs. It's supposed to go away in 2020, as part of the Affordable Care Act. Beneficiaries would pay no more than 25% of brand-name drug costs, while health plans would cover 25% and drug companies would cover the remaining 50% through discount payments.

But the Senate bill would end the coverage gap a year earlier, and change the ratios. Drug companies would be responsible for 70% of the costs instead of 50% — a move that would cost drug companies billions of dollars.

What they're saying: "Rather than prioritizing lowering seniors’ out-of-pocket costs, this proposal provides a massive bailout for insurance companies and undermines their incentive to reduce Part D costs, an incentive that has worked well for more than a decade," said Steve Ubl, the CEO of the Pharmaceutical Research and Manufacturers of America, the industry's leading trade group.

"They were completely blindsided."
— Drug industry lobbyist, referring to PhRMA and companies that sell a lot of Part D drugs

What's next: The budget package is a done deal. But Congress could revisit the issue later, reflecting just how difficult it is to do anything the pharmaceutical industry doesn't like.

  • "I might have written it differently, because I think there are some public policy issues that we’ll probably have to address later on, because it could have an effect of actually raising list prices...we’re going to have to study the impact," said House Energy and Commerce Committee Chairman Greg Walden, adding the proposal came from the Senate.

How it ended up in the deal, per a congressional aide: "This proposal has been around for years, dating back to the Obama budgets, and it’s been a part of these discussions for months. In finding offsets for a budget deal of this magnitude, several drug-related offsets were on the table and of those, this was one of three that were agreed to by all sides."

The bottom line: PhRMA will probably lobby to get rid of the provision, but ultimately it's much more palatable than other ideas out there — including the CREATES Act, which would make it easier for generics to get to market.

  • "I think they can live with that provision," one GOP lobbyist said. "CREATES would have increased competition and taken away one of the ways they protect their products and had a much bigger impact on drug prices."

Sign up for Axios newsletters to get our smart brevity delivered to your inbox every morning. 

Go deeper

Ina Fried, author of Login
52 mins ago - Technology

Google's parent shuts down effort to deliver internet via balloons

Image: Loon

Alphabet is shutting down Loon, one of its "moonshots," which aimed to deliver internet service via high-altitude balloons.

Why it matters: The effort was one of several approaches designed to get high-speed connectivity to some of the world's most remote spots and proved useful in the aftermath of disasters that shut down traditional infrastructure.

Dave Lawler, author of World
1 hour ago - World

What has and hasn't changed as Biden takes over U.S. foreign policy

Photo Illustration: Brendan Lynch/Axios. Photo: Chip Somodevilla/Getty Images

President Biden swiftly recommitted the U.S. to the Paris climate pact and the World Health Organization, but America's broader foreign policy is in a state of flux between the Trump and Biden eras.

Driving the news: One of the most striking moves from the Biden administration thus far was a show of continuity — concurring with the Trump administration's last-minute determination that China had committed "genocide" against Uyghur Muslims.

Updated 3 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Health: New coronavirus cases down, but more bad news ahead — Fighting COVID-19's effects on gender equality.
  2. Politics: Biden unveils "wartime" COVID strategyBiden's COVID-19 bubble.
  3. Vaccine: NYC postpones vaccine appointments following shipment delays — Private companies step in to fill vaccine logistics vacuum.
  4. World: Biden will order U.S. to rejoin World Health OrganizationBiden to bring U.S. into global COVAX initiative for equitable vaccine access.